Savara (NASDAQ:SVRA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Savara (NASDAQ:SVRA) in a report issued on Tuesday, Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright also issued estimates for Savara’s FY2025 earnings at ($0.46) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at $0.01 EPS and FY2028 earnings at $0.23 EPS.

Other research analysts also recently issued research reports about the company. Guggenheim lifted their price target on Savara from $8.00 to $10.00 and gave the stock a buy rating in a research note on Thursday, June 27th. Oppenheimer raised their price target on Savara from $11.00 to $15.00 and gave the stock an outperform rating in a research report on Wednesday, June 26th. Finally, JMP Securities restated a market outperform rating and issued a $9.00 price objective on shares of Savara in a research report on Monday, September 9th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of Buy and a consensus price target of $11.17.

Savara Stock Down 2.3 %

SVRA opened at $3.81 on Tuesday. The stock has a market capitalization of $526.50 million, a P/E ratio of -10.30 and a beta of 0.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. Savara has a one year low of $3.12 and a one year high of $5.70. The business’s 50-day simple moving average is $4.29 and its 200-day simple moving average is $4.44.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Analysts anticipate that Savara will post -0.44 EPS for the current year.

Institutional Investors Weigh In On Savara

Hedge funds and other institutional investors have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co acquired a new position in Savara during the first quarter worth approximately $35,000. Choreo LLC purchased a new position in shares of Savara in the 2nd quarter worth $59,000. DRW Securities LLC acquired a new position in Savara in the second quarter valued at $62,000. Principal Financial Group Inc. grew its position in Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the period. Finally, Profund Advisors LLC acquired a new stake in Savara during the second quarter worth about $105,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.